.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,129,248

« Back to Dashboard

Details for Patent: 7,129,248

Title:Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
Inventor(s): Chapman; Robert (North Kingstown, RI), Rider; Lonn S. (Warwick, RI), Hong; Qi (Sharon, MA), Kyle; Donald (Newtown, PA), Kupper; Robert (Coventry, RI)
Assignee: Euro-Celtique, S.A. (Luxembourg, LU)
Filing Date:Mar 30, 2005
Application Number:11/093,626
Claims:1. A process for preparing an oxycodone hydrochloride composition having less than 25 ppm 14-hydroxycodeinone comprising hydrogenating an oxycodone hydrochloride composition having at least 100 ppm 14-hydroxycodeinone in a suitable solvent to produce an oxycodone hydrochloride composition having less than 25 ppm 14-hydroxycodeinone.

2. The process of claim 1, wherein said hydrogenation is performed with a hydrogen donor and a catalyst.

3. The process of claim 1 wherein said hydrogenation is performed under reflux.

4. The process of claim 1, wherein the solvent is an alcohol.

5. The process of claim 4, wherein the alcohol is selected from the group consisting of methanol, ethanol and isopropanol.

6. The process of claim 1, further comprising recovering the oxycodone hydrochloride composition having less than 25 ppm 14-hydroxycodeinone from the solvent.

7. The process of claim 6, wherein the recovery step comprises crystallizing the oxycodone hydrochloride composition having less than 25 ppm 14-hydroxycodeinone and filtering the crystallized composition from the solvent.

8. The process of claim 6, comprising further hydrogenating the oxycodone hydrochloride composition having less than 25 ppm 14-hydroxycodeinone.

9. The process of claim 6, wherein the oxycodone hydrochloride composition has a 14-hydroxycodeinone level of less than 15 ppm.

10. The process of claim 2, wherein the hydrogenation is performed with a hydrogen donor.

11. The process of claim 10, wherein the hydrogenation is further performed with a catalyst.

12. The process of claim 10, wherein the hydrogen donor is selected from the group consisting of hydrogen gas, formic acid, indoline, cyclohexene, sodium borohydride, tetrahydroquinoline, 2,5-dihydrofuran, phosphoric acid, and combinations thereof.

13. The process of claim 1, wherein the hydrogenation produces an oxycodone hydrochloride composition having a 14-hydroxycodeinone level of less than 15 ppm.

14. The process of claim 1, wherein the hydrogenation produces an oxycodone hydrochloride composition having a 14-hydroxycodeinone level of less than 10 ppm.

15. The process of claim 1, wherein the hydrogenation produces an oxycodone hydrochloride composition having a 14-hydroxycodeinone level of less than 5 ppm.

16. The process of claim 1, wherein the hydrogenation produces an oxycodone composition having a 14-hydroxycodeinone level of between 15 ppm and 25 ppm, further comprising additional hydrogenation to produce an oxycodone hydrochloride composition comprising 14-hydroxycodeinone in an amount less than 10 ppm.

17. The process of claim 1, wherein the hydrogenation produces an oxycodone composition having a 14-hydroxycodeinone level of between 10 ppm and 25 ppm, further comprising additional hydrogenation to produce an oxycodone hydrochloride composition comprising 14-hydroxycodeinone in an amount less than 5 ppm.

18. The process of claim 1, wherein the hydrogenation step is performed without a hydrogen gas feed.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc